A comprehensive proteomics and drug screening study in pan-cancer models confirmed that FAT1 mutations in head and neck squamous cell carcinoma (HNSCC) sensitize cells to the BET inhibitor JQ1, whereas esophageal squamous cell carcinoma (ESCC) and other cancers exhibit different resistance patterns (31). The gene discussed is FAT1; the disease is cancer.